# Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

> **NCT02101593** · PHASE1 · COMPLETED · sponsor: **Polaris Group** · enrollment: 8 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** ADI-PEG 20

## Key facts

- **NCT ID:** NCT02101593
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-02
- **Final completion:** 2016-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101593, "Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02101593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*